Aharon Schwartz

Alcobra Ltd. engages in the research, development, and market of pharmaceutical productsfor the treatment of central nervous system disorders and cognitive dysfunctions. Its portfolio includes Metadoxine Extended Release to treat Attention Deficit Hyperactivity Disorder and Fragile X Syndrome. The company was founded by Ehud Moshe Gilboa and Dalia Megiddo on February 7, 2008 and is headquartered in Tel Aviv, Israel.

DenX Ltd. is engaged in manufacturing of dental equipment. The firm develops and markets image guided technology for dental training and clinical implementation. The company was founded by Hayka Alon in 1994 and is headquartered in Jerusalem, Israel.

Yissum Research Development Co. Ltd. (Yissum Research) is a venture capital subsidiary of The Hebrew University of Jerusalem founded in 1964. The firm is headquartered in Jerusalem, Israel.

Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities.

CureTech Ltd. operates as a biotechnology company. It develops novel and immune modulating products for the treatment and control of cancer. The company was founded by Michael Schickler in 1995 and is headquartered in Yavne, Israel.

Andromeda Biotech Ltd. develops treatment for autoimmune diabetes. The company was founded in 2007 and is headquartered in Rehovot, Israel.

Meytav Technological Enterprises Innovation Center Ltd is an Independent Venture Capital firm founded in 1991. The firm is headquartered in Kiryat Shmona.

BioCancell Therapeutics, Inc. is a development-stage biopharmaceutical company, which is focused on the discovery, development and commercialization of novel therapies for treating cancer-related diseases. The company's technology offers a safe and long-term treatment of cancer, with no adverse effects. The drug candidates developed by the company are targeted and its target is to selectively destroy the cancer cells without affecting healthy cells. BioCancell was founded on July 26, 2004 by Avraham Hochberg and is headquartered in Jerusalem, Israel.

BioMAS Ltd. is an Israeli pharmaceutical company that was founded in 2000. The private company is based in Jerusalem, Israel and develops drugs that are based on tellurium.

Integra Holdings Ltd. operates as a holding company. It invests in the pharmaceutical industry. The company was founded in 2012 and is headquartered in Jerusalem, Israel.

Anthill Scale Ventures is a venture capital firm. The firm was founded in 2016 by Prasad Vanga. The firm headquartered in Hyderabad, India with additional office in Singapore, US and Israel.

Barcode Diagnostics Ltd. is engaged in developing a product that assesses the efficacy of different cancer drugs directly on the tumor within the body to select the optimal personalized treatment for each patient. The company was founded by Ronen Eavri, Annie Sabbah, and Avi Schroeder in February 2017 and is headquartered in Nazareth, Israel.

D Pharm Ltd. provides drug development services.